Fig. 5From: Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpointAZD1775 enhances olaparib’s antitumor efficacy via HR defect in vivo. AZD1775 (30 mg/kg/d, by gavage) with/without olaparib (25 mg/kg/d, ip) were given to mice bearing MKN45 tumors for 21 days (n = 5 per group). a Tumor volume was measured every 3 days after treatment and xenograft growth curves were shown. Data expressed as Mean ± SD. *P < 0.05 by repeated measures ANOVA analysis. b and c FFPE sections were stained with Ki-67 using IHC and tumor lysates were immunoblotted for indicated proteins. Original magnification, 200×. AZD, AZD1775; Ola, olaparib; Com, CombinationBack to article page